Parkinson's Disease
Conditions
Brief summary
The goal of the study is to develop and organize an effort to identify genes that determine an individual's risk for developing Parkinson's disease (PD). 1. To ascertain, study and establish a repository of DNA samples that will allow for the identification of known and yet-to-be-identified genetic markers associated with the development of PD. 2. To create a database with clinical, genetic (HLA, genome screen) and medical history information that will facilitate the search for PD susceptibility genes. 3. To provide a centralized DNA repository to allow for targeted studies of genetic factors contributing to the onset, heterogeneity and progression of PD. 4. To evaluate opportunities to extend the results of research to develop methods of risk prediction, prevention and therapy for PD.
Interventions
GENETICblood draw
The blood collection is designed to obtain blood samples as a source of DNA for genotyping and to establish a plasma and serum storage repository for future assays. GCRC nurses will perform all blood draws associated with this study. The following procedures are designed to standardize sample collection: 1. Blood will be collected with the participant in the seated position with the reclining position reserved for those with a history of fainting during blood collection. 2. Participants will be instructed to drink plenty of water (e.g., at least 8 large glasses of water) prior to the clinic visit as this facilitates easier collection. 3. No fasting, activity or medication restrictions are required prior to or following blood collection. 4. Blood collection will follow completion of the questionnaires. They will be performed by a nurse or technician with documented class time and experience in phlebotomy. Technician certification will occur prior to blood collection.
Sponsors
Northwell Health
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects must have a diagnosis of Parkinson's Disease as determined by standard neurological criteria. * Patients ≥18 years of age who are able to provide informed consent * Patients ≥ 18 who are decisionally impaired for whom informed consent can be obtained by a legally authorized representative.
Exclusion criteria
* Patients without a diagnosis of Parkinson's Disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the current protocol is for establishment of the registry only and not for particular analyses of its contents | 5 years |
Countries
United States
Outcome results
None listed